2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Patients receiving FOLFOX had significantly better progression-free survival (2.93 months vs 1.77 months, p<0.01) and disease control rate (52.17% vs 31.55%, p<0.001) but a nonsignificant trend toward better survival (6.4 months vs 4.97 months, p=0.07). 407 Some results of cisplatin-containing regimens (e.g., in combination with doxorubicin, 408 capecitabine, 409 , 410 or 5-fluorouracil 411 ) or oxaliplatin-containing regimens (e.g., in combination with gemcitabine 412 or capecitabine 413 ) for HCC have been reported, but the benefits of these regimens compared to monotherapy are still lacking.

also in 5,406 other papers

Diagnosis should be based on the combination of the identification of the typical hallmark of HCC in two or more imaging modalities and increased serum AFP with an increasing trend over time for liver nodules <1 cm in patients with suppressed hepatitis activity. 57 Biopsy should be considered for atypical nodules not meeting the noninvasive criteria.

also in 63,971 other papers

The PIAF regimen (cisplatin/interferon a-2b/doxorubicin/fluorouracil) shows better objective response rates (20.9% vs 10.5%, p=0.058) and median overall survival (8.67 months vs 6.83 months; RR, 0.97; p=0.830), although the difference failed to reach statistical significance.

also in 6,035 other papers